| Literature DB >> 32647483 |
Auriekson N Queiroz1, Camila C Martins1, Kelton L B Santos1,2, Ederson S Carvalho1, Alex O Owiti3, Karen R M Oliveira4, Anderson M Herculano4, Albérico B F da Silva5, Rosivaldo S Borges1.
Abstract
Edaravone is a heteEntities:
Keywords: Antioxidant; DFT; DPPH; Edaravone; Heterocycles; Isoxazolone; Tautomerism
Year: 2020 PMID: 32647483 PMCID: PMC7335820 DOI: 10.1016/j.jsps.2020.06.001
Source DB: PubMed Journal: Saudi Pharm J ISSN: 1319-0164 Impact factor: 4.330
Fig. 1Edaravone (1–3) and isoxazolone derivatives (4–6) and their tautomers (a-c), where R is H, CH or C and X = O or N.
Fig. 2Heterocycle derivatives of edaravone (7) and phenylisoxazolone (8) and their tautomers a (C—H), b (N—H) and c (O—H).
Energy differences for edaravone and isoxazolone tautomers in different media.
| Tautomers | ΔEgas phase (kcal.mol−1) | ΔECHCl3 (kcal.mol−1) | ΔEEtOH (kcal.mol−1) | ΔEH2O (kcal.mol−1) |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| 4.14 | 2.43 | 1.70 | 1.56 | |
| 4.40 | 4.36 | 4.23 | 4.20 | |
| 0 | 0 | 0 | 0 | |
| 5.03 | 3.44 | 2.77 | 2.64 | |
| 6.30 | 6.68 | 6.68 | 6.67 | |
| 0 | 0 | 0 | 0 | |
| 5.19 | 3.61 | 2.95 | 2.82 | |
| 6.96 | 6.97 | 6.81 | 6.77 | |
| 0 | 0 | 0 | 0 | |
| 2.17 | 1.46 | 1.26 | 1.22 | |
| 6.02 | 6.47 | 6.59 | 6.61 | |
| 0 | 0 | 0 | 0 | |
| 2.96 | 2.31 | 2.16 | 2.14 | |
| 8.53 | 9.23 | 9.41 | 9.44 | |
| 0 | 0 | 0 | 0 | |
| 2.51 | 1.78 | 1.63 | 1.61 | |
| 8.08 | 8.36 | 8.33 | 8.32 | |
| 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | |
| −4.04 | −3.37 | −2.97 | −2.88 | |
| −9.04 | −5.80 | −4.44 | −4.18 | |
| 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | |
| −0.88 | −0.02 | 0.72 | 0.89 | |
| 7.73 | 7.79 | 7.66 | 7.63 | |
Theoretical properties of edaravone and isoxazolone tautomeric forms in gas phase calculated at the B3LYP 6-31++G(2d, 2p) level.
| Tautomers | HOMO (eV) | LUMO (eV) | GAP (eV) | AIP (kcal.mol−1) | BDEXH (kcal.mol−1) |
|---|---|---|---|---|---|
| −6.19 | −1.40 | 4.78 | 179.83 | 81.93 | |
| −6.08 | −1.20 | 4.88 | 176.48 | 77.93 | |
| −6.32 | −0.78 | 5.54 | 181.33 | 77.71 | |
| −6.03 | −1.22 | 4.81 | 175.03 | 82.88 | |
| −5.97 | −1.09 | 4.88 | 172.70 | 78.17 | |
| −6.12 | −0.68 | 5.45 | 175.80 | 76.91 | |
| −5.95 | −2.01 | 3.95 | 168.78 | 82.92 | |
| −6.00 | −1.88 | 4.12 | 170.25 | 77.96 | |
| −5.90 | −1.23 | 4.67 | 167.25 | 76.92 | |
| −8.05 | −1.64 | 6.41 | 238.43 | 86.13 | |
| −1.38 | 5.63 | 205.62 | 84.29 | ||
| −6.91 | −0.86 | 6.05 | 210.55 | 80.34 | |
| −7.87 | −1.39 | 6.48 | 225.78 | 87.21 | |
| −6.47 | −0.74 | 5.73 | 199.20 | 84.77 | |
| −6.73 | −0.79 | 5.94 | 203.18 | 79.11 | |
| −7.11 | −2.19 | 4.92 | 198.90 | 87.16 | |
| −6.83 | −2.09 | 4.75 | 193.25 | 84.93 | |
| −6.65 | −1.37 | 5.28 | 189.33 | 79.31 | |
| −6.28 | −1.18 | 5.09 | 181.65 | 83.39 | |
| −6.22 | −1.24 | 4.98 | 178.33 | 81.24 | |
| −6.01 | −1.32 | 4.68 | 173.32 | 85.95 | |
| −6.06 | −1.50 | 4.56 | 164.04 | 90.80 | |
| −7.40 | −2.42 | 4.98 | 205.84 | 86.60 | |
| −7.35 | −2.39 | 4.96 | 204.84 | 87.47 | |
| −6.26 | −2.30 | 3.96 | 189.38 | 87.88 | |
| −6.48 | −1.29 | 5.19 | 194.40 | 79.24 | |
Fig. 3HOMO topology of the most stable tautomers in gas phase calculated at the B3LYP 6-31++G(2d,2p) level.
Fig. 4Contribution of free radical cation spin density among the most stable tautomers of edaravone (2a), pyridinyl edaravone (7b and 7c) and isoxazolones (6a and 8b).
Fig. 5Contribution of spin density of semiquinones among the most stable tautomers of edaravone (2a), pyridinyl edaravone (7b and 7c) and isoxazolones (6a and 8b).
Fig. 6Evaluation of scavenging capacity of edaravone (2) and isoxazolone (6) at different concentrations (250-1 μM) in methanolic solution against DPPH radical (25 μM).